General description
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1D20 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects Inducible T-cell costimulator (ICOS/CD278). It targets an epitope within 20 amino acids from the C-terminal region.
Immunogen
KLH-conjugated linear peptide corresponding to 20 amino acids from the C-terminal, cytoplasmic domain of human Inducible T-cell costimulator (ICOS/CD278).
Application
Quality Control Testing
Evaluated by Western Blotting in K562 cell lysate.
Western Blotting Analysis: A 1:10,000 dilution of this antibody detected ICOS/CD278 in K562 cell lysate.
Tested Applications
Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected ICOS/CD278 in HUT-78 cell lysates.
Flow Cytometry Analysis: 0.1 µg from a representative lot detected ICOS/CD278 in one million Human peripheral blood mononuclear cells (PBMC).
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected ICOS/CD278 in K562 cells.
Affinity Binding Assay: A representative lot of this antibody bound ICOS/CD278 peptide with a KD of 6.7 x 10-11 in an affinity binding assay.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Inducible T-cell costimulator (UniProt: Q9Y6W8; also known as Activation-inducible lymphocyte immunomediatory molecule, CD278) is encoded by the ICOS (also known as AILIM) gene (Gene ID: 29851) in human. ICOS is a disulfide-linked, homodimeric, single-pass type I membrane glycoprotein that is synthesized with a signal peptide (aa 1-20), which is subsequently cleaved off to produce the mature protein that contains an extracellular domain (aa 21-140), a transmembrane domain (aa 141-161), and a cytoplasmic domain (aa 162-199). It serves as an inducible costimulatory molecule and is expressed on activated CD4+ T cells. It is highly expressed on tonsillar T-cells, which are closely associated with B-cells in the apical light zone of germinal centers, the site of terminal B-cell maturation. It binds to an ICOS ligand expressed by B-cells, macrophages, and dendritic cells. It is reported to enhance all basic T-cell responses to a foreign antigen and is essential both for efficient interaction between T and B-cells and for normal antibody responses to T-cell dependent antigens. ICOS is reported to co-induce a variety of cytokines, including IL-4, IL-5, IL-6, IFN- , TNF- , and GM-CSF. It is reported to superinduce IL-10, but not IL-2. It also plays a critical role in CD40-mediated class switching of immunoglobin isotypes. Mutations in ICOS gene have been linked to Immunodeficiency, common variable, 1 (CVID1) that is characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. Two isoforms of ICOS have been described that are produced by alternative splicing. Isoform 1 is membrane associated protein and isoform 2 is a secreted protein. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonal. (Ref.: Grimbacher, B., et al. (2003). Nat. Immunol. 4(3); 261-268; Beier, KC., et al. (2000). Eur. J. Immunol. 30(12); 3707-3017; Hutloff, A., et al. (1999). Nature. 397(6716); 263-266).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.